אינג'י 10 מג80 מג טבליות

País: Israel

Idioma: hebreo

Fuente: Ministry of Health

Ingredientes activos:

EZETIMIBE; SIMVASTATIN

Disponible desde:

MERCK SHARP & DOHME ISRAEL LTD

Código ATC:

C10AA01

formulario farmacéutico:

טבליה

Composición:

EZETIMIBE 10 MG; SIMVASTATIN 80 MG

Vía de administración:

פומי

tipo de receta:

מרשם נדרש

Fabricado por:

MERCK SHARP & DOHME (ITALIA) S.P.A.

Grupo terapéutico:

SIMVASTATIN

Área terapéutica:

SIMVASTATIN

indicaciones terapéuticas:

Hypercholesterolemia: Inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. Inegy contains ezetimibe and simvastatin. Simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. Studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. Homozygous familial hypercholesterolemia (HoFH): Inegy is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [LDL] apheresis).

Fecha de autorización:

2012-04-30